The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

2019-12-19T21:12:13+00:00December 5th, 2019|Categories: Press Releases|Tags: , , , , , , , , |

⟵  PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]